Hpx Corp Cl A (NY: HPX )

N/A UNCHANGED

Last Price Updated: 8:00 PM EST, Mar 3, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Hpx Corp Cl A

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

March 03, 2023

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

Via Benzinga

Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday

March 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Dow Surges Over 100 Points; US Services PMI Rises In February

March 03, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded up 0.42% to 33,140.85 while the NASDAQ rose 1.02%...

Via Benzinga

Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

March 02, 2023

Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...

Via Benzinga

Why Salesforce Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

March 02, 2023

Gainers

Via Benzinga

HPX Stock Soars 200% After Shareholders Approve Proposed Merger

March 01, 2023

Although HPX's dramatic rise underscores renewed SPAC and IPO enthusiasm, investors should approach HPX stock cautiously.

Via InvestorPlace

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.